🇪🇺·Sep 7Research
Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors.
Publisher
E
Europe PMC
EU
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Europe PMC
- Region
- EU
- Scope
- Research
- Published
- September 7, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on europepmc.org
Leave the platform to read the original full article on the publisher site.
Source: Europe PMC
Scope: Research
Related coverage
More related coverage
Crossref/16h ago
Evaluating the Clinical Use of Cefoperazone/ Sulbactam and Post-discharge Antibiotics Practices in Infectious Diseases Patients
Crossref/16h ago
Polycystic Ovary Syndrome (PCOS) -Associated Infertility: Clinical Insights and Emerging Deep Learning Approaches for Early Detection and Prediction
Crossref/16h ago
Low-Dose Silodosin for Premature Ejaculation: A Clinical Evaluation
Crossref/16h ago